Join the 'Taxol' group to help and get support from people like you. How it works
Taxol Blog
| Tweet |
Many Primary Care Docs Don't Know Long-Term Effects of Chemo: Survey
Posted 12 days ago by Drugs.com
WEDNESDAY, May 16 – Many primary care doctors don't know the long-term side effects of the chemotherapy treatments that cancer survivors under their care may have been given, a new survey found. On the other hand, most oncologists – though not all – are familiar with the side effects of four common treatments used to treat breast and colon cancer, according to the results of the survey being presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. "While oncologists commonly identify the main late effects of four common cancer drugs, primary care providers did not," study author Dr. Larissa Nekhlyudov said during a Wednesday news conference. "This is not surprising in that primary care providers have different training and exposure to chemotherapy drugs," she noted. "However, these findings emphasize that in the transition of patients ... Read more
Related support groups: Cancer, Zyprexa, Reglan, Olanzapine, Nausea/Vomiting -- Chemotherapy Induced, Metoclopramide, Zyprexa Zydis, Cytoxan, Adriamycin, Cyclophosphamide, Oxaliplatin, Taxol, Paclitaxel, Doxorubicin, Zyprexa Intramuscular
Cancer Patients Should Ask Doctors to Use Simple Terms
Posted 28 Sep 2011 by Drugs.com
WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more
Related support groups: Cancer, Methotrexate, Provera, Breast Cancer, Lupron, Accutane, Depo-Provera, Prostate Cancer, Tamoxifen, Femara, Arimidex, Lupron Depot, Medroxyprogesterone, Claravis, Fluorouracil
Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study
Posted 9 Aug 2011 by Drugs.com
MONDAY, Aug. 8 – Countering conventional wisdom, researchers in France say that elderly lung cancer patients can gain significant benefit from an aggressive, double-barreled chemotherapy that's often used in younger patients. The finding raises questions about standard public health recommendations, such as those issued the American Society of Clinical Oncology in 2004, which advised physicians not to expose elderly patients with non-small cell lung cancer (NSCLC) to the undesirable side effects of combination chemotherapy. Instead, older patients have typically been offered less harsh – but also less effective – chemotherapies containing a single agent. That's because, until now, it's been assumed that the benefits to elderly patients of dual-chemo ("doublet") regimens simply weren't worth their onerous side effects and risks. But, "our study demonstrates clearly that [the doublet] ... Read more
Related support groups: Lung Cancer, Carboplatin, Gemzar, Gemcitabine, Taxol, Paclitaxel, Vinorelbine, Navelbine, Onxol, Carboplatin Novaplus, Paraplatin
New Chemo Regimen May Benefit Ovarian Cancer Patients
Posted 2 Feb 2010 by Drugs.com
SUNDAY, Sept. 20 – Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings. This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous ... Read more
Related support groups: Ovarian Cancer, Taxol, Paclitaxel, Onxol
Taxol Boosts Odds of Chronic Pain
Posted 1 Dec 2009 by Drugs.com
MONDAY, Nov. 30 – The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows. It included 240 women who took part in clinical trials of Taxol between 1994 and 2001. Those who experienced chemotherapy-induced peripheral neuropathy during their treatment with Taxol were three times more likely to eventually be diagnosed with chronic neuropathic pain. The study is published in the November issue of the Journal of Pain. The findings indicate that patients treated with Taxol should be regularly monitored for neuropathic pain after their chemotherapy ends, said the researchers from the University of Texas M.D. Anderson Cancer Center. In certain cases, patients and doctors should review the risks and benefits for continuing treatment with Taxol if a patient is likely to experience worsening neuropathy, the study ... Read more
Related support groups: Taxol
Ask a Question
Further Information
Related Condition Support Groups
Non-Small Cell Lung Cancer, Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic, Kaposi's Sarcoma, Breast Cancer -- Adjuvant, Wilms' Tumor